Brief: Kiromic Biopharma Received Letter From Nasdaq That Co Has Been Granted 180-Day Extension To March 13, 2023 To Regain Compliance
20/09/2022 21:40
Sept 20 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC BIOPHARMA - ON SEPT 15, CO RECEIVED LETTER FROM
NASDAQ
THAT CO HAS BEEN GRANTED 180-DAY EXTENSION TO MARCH 13, 2023 TO
REGAIN COMPLIANCE
Further company coverage: KRBP.O
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site